AXSMAxsome Therapeutics, Inc.vs its industry peers
A metric-by-metric comparison of Axsome Therapeutics, Inc. against iShares Biotechnology ETF holdings — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| 기업 | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AXSM본 종목 | $11.0B#14 | — | 132.6x#13 | 17.3x#8 | 65.5%#3 | 36.2%#9 | -26.1%#12 | -219.9%#14 | — | — | 78.0%#5 | — |
| VRTX | $128.7B#4 | 29.6x#5 | 6.4x#3 | 10.7x#7 | 8.9%#9 | 838.1%#3 | 34.8%#2 | 19.5%#6 | 25.0%#5 | — | 31.1%#12 | — |
| AMGN | $207.2B#2 | 23.8x#4 | 17.7x#8 | 5.6x#3 | 10.0%#8 | 88.5%#7 | 24.7%#7 | 66.0%#2 | 15.1%#7 | — | 42.5%#8 | 2.5%#1 |
| GILD | $186.5B#3 | — | 15.8x#7 | 6.3x#4 | 2.4%#10 | 1672.9%#2 | 34.0%#3 | 71.9%#1 | 26.7%#4 | — | 35.3%#10 | 2.1%#2 |
| REGN | — | 19.4x#2 | — | — | 1.0%#12 | 2.1%#11 | 24.9%#6 | 14.2%#7 | 9.4%#9 | — | 31.3%#11 | — |
| ARGX | $61.8B#6 | — | — | 1738.8x#13 | 254.4%#1 | 55.1%#8 | 2965.7%#1 | — | — | — | 36.5%#9 | — |
| ALNY | $32.7B#10 | 42.5x#6 | 24.1x#9 | 8.8x#6 | 65.2%#4 | 212.8%#4 | 13.5%#9 | 23.2%#4 | 150.5%#1 | — | -46.0%#15 | — |
| NTRA | $52.0B#7 | — | 28.5x#10 | 22.5x#9 | 35.9%#6 | -9.3%#12 | -13.4%#11 | -11.4%#10 | -18.0%#10 | — | 100.5%#4 | — |
| RVMD | $40.9B#8 | — | 15.7x#6 | — | — | -88.5%#15 | — | -43.4%#12 | — | — | 322.2%#2 | — |
| BIIB | $32.1B#11 | 23.4x#3 | 2.2x#1 | 3.2x#1 | 2.2%#11 | -20.8%#13 | 28.7%#5 | 8.7%#8 | 13.0%#8 | 4#3 | 51.3%#6 | — |
| ILMN | $36.5B#9 | 45.0x#7 | 12.8x#5 | 8.4x#5 | -0.7%#13 | 169.5%#5 | 18.6%#8 | 30.0%#3 | 22.0%#6 | 7#1 | 134.2%#3 | — |
| MRNA | $62.1B#5 | — | 9.2x#4 | 32.0x#10 | -39.9%#14 | 20.8%#10 | -158.1%#13 | -41.7%#11 | -54.6%#11 | — | 510.6%#1 | — |
| INSM | $26.8B#12 | — | 35.4x#11 | 44.3x#11 | 66.7%#2 | -39.7%#14 | -205.6%#14 | -168.6%#13 | -163.0%#12 | 3#4 | -15.8%#14 | — |
| ONC | $519.0B#1 | 816.6x#8 | 100.3x#12 | 97.1x#12 | 40.2%#5 | 144.5%#6 | 8.4%#10 | 5.5%#9 | 29.9%#3 | 6#2 | 2.5%#13 | — |
| INCY | $25.7B#13 | 18.1x#1 | 4.6x#2 | 5.0x#2 | 21.2%#7 | 3846.9%#1 | 29.5%#4 | 22.9%#5 | 49.0%#2 | — | 49.4%#7 | — |
Peer set: top holdings of IBB (iShares Biotechnology ETF), the indexed fund holding this stock at its highest weight — a fund manager's grouping, not Tickwind's judgement. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-09-18.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice